Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 16/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10158773 | 0.96 | ADORA3 (0.56) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL10194938 | 0.94 | ADORA3 (0.49) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL3026932 | 0.93 | ADORA3 (0.59) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL10156799 | 0.92 | ADORA3 (0.52) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL10156671 | 0.92 | ADORA3 (0.54) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL10156788 | 0.91 | ADORA3 (0.52) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL10156761 | 0.91 | ADORA3 (0.51) | ADORA3ADORA1ADORA2A | |
| SCHEMBL10156738 | 0.90 | ADORA3 (0.49) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL10156717 | 0.89 | ADORA3 (0.49) | ADORA3ADORA1ADORA2A | |
| SCHEMBL10194326 | 0.87 | ADORA3 (0.49) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | ADORA3 1044/4885ADORA1 697/4885ADORA2A 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.